Research Indicates Geron Corporation's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the presentation of research studies indicating that GRNOPC1, the company’s human embryonic stem cell (hESC)-based therapeutic for the treatment of spinal cord injury, evades a direct attack by the human immune system. Presented by Geron scientist Ross Okamura at the Federation of Clinical Immunology Societies meeting in San Diego, the findings could mean that patients treated with GRNOPC1 would require significantly lower doses and/or shorter courses of immunosuppression than what are required for patients who undergo solid organ transplants.